Pembrolizumab + Pemetrexed + Abemaciclib
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Grade Glioma
Conditions
High Grade Glioma
Trial Timeline
Jul 8, 2020 → Jul 8, 2020
NCT ID
NCT04220892About Pembrolizumab + Pemetrexed + Abemaciclib
Pembrolizumab + Pemetrexed + Abemaciclib is a phase 1 stage product being developed by Eli Lilly for High Grade Glioma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04220892. Target conditions include High Grade Glioma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04220892 | Phase 1 | Withdrawn |
Competing Products
20 competing products in High Grade Glioma